Ahmad E, Lim S, Lamptey R, et al
Talk to your prescriber if you are concerned that your prescription for Rybelsus exceeds the supply covered by your Blue Cross and Blue Shield Association plan (or plan provided by an independent licensee of Blue Cross)
The study showed a 13% reduction in major adverse cardiovascular events (MACE), a composite endpoint for cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, in patients treated with liraglutide compared with placebo at a mean follow-up of 3.8 years (hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.780.97) and a significant reduction in cardiovascular death (HR 0.78, 95% CI 0.660.93)
After this period, we recommend discarding it to ensure safety and efficacy
Glutathione infused Brightens dull skin & reduces pigmentation